1635P Impact of treatment sequence on clinical outcomes in patients with thymic carcinoma

Abstract

Thymic carcinoma is a rare cancer with a poor prognosis in unresectable cases. There is no established standard chemotherapy for the treatment of thymic carcinoma because evidence has been obtained in single-arm trials with a small number of patients. In clinical practice, carboplatin +paclitaxel (CP), S-1 (oral fluorouracil), sunitinib, and lenvatinib have been used in Japan. However, the clinical impact of these chemotherapy regimens remains unclear. In addition, some patients receiving these treatments experience only increased liver metastases.